The downregulation of SOX10 predominantly tends to induce the senescent phenotype and compensatory reactivation of receptor tyrosine kinases in this phase, rather than to suppress tumor cell survival.76–78 Therefore, the biological effect of SOX10 in melanoma targeted therapy is context-dependent, raising the notion that the intervention of SOX10 expression for overcoming resistance to targeted therapy should take the phases and paradigms of drug resistance into consideration. This evidence concerns the gene SOX10 and melanoma.